Alzheimer's Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004 August 18, 2023 12:39 PM Eastern Daylight Time GROTON, Conn.--(BUSINESS WIRE)--Astrocyte Pharmaceuticals Inc., a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer's Drug Discovery Foundation, and other investors. The funding will accelerate the clinical development of AST-004, a highly promising therapeutic candidate aimed at treating a broad array of acute brain injuries [ Read more... ]
By Mid Atlantic Bio Angels|2023-08-29T19:27:52+00:00August 26th, 2023|Categories: Press news|Comments Off on MABA Portfolio Company Astrocyte Pharmaceuticals Raises $6M Pre-Series B Financing Round
Mid Atlantic Bio Angels group (MABA), is an angel investor group focused exclusively on new and emerging life science companies.
Membership in MABA is by invitation only, and is extended to active, accredited investors (life science angels) who wish to make investments in life science companies, as well as institutional investors and life science company venture arms wishing to invest alongside the angels.